Social values and scientific evidence: The case of the HPV vaccines

Biology and Philosophy

Volumn 25, Issue 2, 2010, Pages 203-213

  Intemann, Kristen ^a   de Melo Martín, Inmaculada ^b  

^a MONTANA STATE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Evidence for use; HPV vaccine; Values in science

Indexed keywords

DRUG DEVELOPMENT; ETHICS; RESEARCH WORK; VACCINE;

HUMAN PAPILLOMAVIRUS;

EID: 78650684941     PISSN: 01693867     EISSN: 15728404     Source Type: Journal    
DOI: 10.1007/s10539-009-9191-9     Document Type: Article

References (40)

1. Adam Y, van Gelderen CJ, de Bruyn G, McIntyre JA, Turton DA, Martinson NA (2008) Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population. BMC Cancer 8:211
2. Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, Rwambuya S, Walker CJ, Kambugu FS, Abdul-Karim FW, Whalen CC, Salata RA (2007) Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 79(6):758-765
3. Bosch FX, Lorincz A, Munoz N et al (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265
4. Cartwright N (2007) Are RCTs the gold standard? BioSocieties 2:11-20
5. Clifford GM et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490):991-998
6. Douglas H (2007) Rejecting the ideal of value-free science. In: Kincaid H, Dupré J, Wylie A (eds) Value- free science? Ideals and illusions. Oxford University Press, New York, pp 120-139
7. Downs LS, Smith JS, Scarinci I, Flowers L, Parham G (2008) The disparity of cervical cancer in diverse populations. Gynecol Oncol 109(2 Suppl):S22-S30
8. Dunne EF, Markowitz LE (2006) Genital human papillomavirus infection. Clin Infect Dis 43(5):624-629
9. Dupré J (2007) Fact and value. In: Kincaid H, Dupré J, Wylie A (eds) Value-free science? Ideals and illusions. Oxford University Press, New York, pp 27-41
10. Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaétan J, Coursaget P, Veramendi J (2008) Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 6(5):427-441
11. Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D (2007) Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 14(10):1285-1295
12. Franco EL, Harper DM (2005) Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23:2388-2394
13. Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4(1):46-54
14. García Carrancá A, Galván SC (2007) Vaccines against human papillomavirus: perspectives for controlling cervical cancer. Expert Rev Vaccines 6(4):497-510
15. Garland SM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928-1943
16. Grossman J, Mackenzie FJ (2005) The randomized controlled trial: gold standard, or merely standard? Perspect Biol Med 48(4):516-534
17. Harper DM (2008) Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 110(3 Suppl 1):S11-S17
18. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255
19. Hildesheim A et al (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7):743-753
20. Kahn JA, Burk RD (2007) Papillomavirus vaccines in perspective. Lancet 369(9580):2135-2137
21. Kitcher P (2001) Science, truth, and democracy. Oxford University Press, New York
22. Kourany J (2003) A philosophy of science for the twenty-first century. Philosophy Science 70:1-14
23. Longino H (2002) The fate of knowledge. Princeton University Press, Princeton
24. Moniz M, Ling M, Hung CF, Wu TC (2003) HPV DNA vaccines. Front Biosci 8:d55-d68
25. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111(2):278-285
26. Nallamothu BK, Hayward RA, Bates ER (2008) Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 118(12):1294-1303
27. Paavonen J., et al (2007) HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580):2161-2170 Erratum in: Lancet 370(9596):1414
28. Pagliusi SR, Teresa Aguado M (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23(5):569-578
29. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55(2):74-108
30. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB (2000) Evidence-based medicine: how to practice and teach EBM, 2nd edn. Churchill Livingstone, Edinburgh
31. Safaeian M, Solomon D, Castle PE (2007) Cervical cancer prevention-cervical screening: science in evolution. Obstet Gynecol Clin North Am 34(4):739-760
32. Schiller JT, Lowy DR (1996) Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 7(6):373-382
33. Schiller JT, Nardelli-Haefliger D (2006) Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine 24(Suppl 3:S3):147-153
34. Solomon M (2001) Social empiricism. MIT Press, Cambridge
35. Suba EJ, Murphy SK, Donnelly AD, Furia LM, Huynh ML, Raab SS (2006) Systems analysis of real- world obstacles to successful cervical cancer prevention in developing countries. Am J Public Health 96(3):480-487
36. The Future II Study Group (2007a) Quadrivalent vaccine against human papillomavirus to prevent high- grade cervical lesions. N Engl J Med 356:1915-1927
37. The Future II Study Group (2007b) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868
38. U.S. Cancer Statistics Working Group (2007) United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute
39. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, Clements JD, Rose RC (2003) Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77(16):8702-8711
40. World Health Organization (WHO) (2008) Viral cancer. Human papillomavirus. Available from http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html